Show simple item record

dc.contributor.authorMalhan, S.
dc.contributor.authorGuler, S.
dc.contributor.authorYetkin, I.
dc.contributor.authorIgnacio, T.J.
dc.contributor.authorVerheggen, B.
dc.contributor.authorCharokopou, M.
dc.date.accessioned2019-10-06T11:36:51Z
dc.date.available2019-10-06T11:36:51Z
dc.date.issued2015
dc.identifier.issn1098-3015
dc.identifier.urihttps://www.valueinhealthjournal.com/article/S1098-3015(15)04172-8/pdf
dc.identifier.urihttp://hdl.handle.net/11727/4055
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.jval.2015.09.2096en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleDAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTINGen_US
dc.typeconferenceObjecten_US
dc.relation.journalVALUE IN HEALTHen_US
dc.identifier.volume18en_US
dc.identifier.issue7en_US
dc.identifier.startpageA607en_US
dc.identifier.endpageA607en_US
dc.identifier.wos000209861300568en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record